Project Grant R61AG090361
Award Date
3/19/25
Completion Date
2/28/27
Dollars Obligated
$835K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $613,571 to the University of Chicago to develop and test a novel therapy for Alzheimer's disease (AD). The key products and services to be delivered include:
Development of two chimeric antigen receptor (CAR) constructs that specifically target amyloid-beta (Aβ) and promote phagocytosis via the TREM2 or Fc receptor signaling pathways. The CAR constructs will be packaged in lipid...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $810,596 to New York University School of Medicine to develop a novel chimeric antigen receptor (CAR) macrophage therapy for Alzheimer's disease (AD). The project aims to create "off-the-shelf" human induced pluripotent stem cell-derived macrophages/microglia engineered with CARs targeting amyloid-beta, a key pathological protein in AD. Key objectives include optimizing the...
This $704,198 Project Grant award, funded under the National Institute on Aging's Aging Research program (CFDA 93.866), supports research to develop a novel chimeric antigen receptor (CAR) T-cell therapy for Alzheimer's disease (AD). The award to Trustees of Dartmouth College aims to enhance the persistence of CAR-modified regulatory T cells (CAR Tregs) in the central nervous system (CNS) to rebalance cerebral immunity, promote amyloid-beta clearance, and limit neuronal damage in AD. The key...
This $734,778 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the development of a novel allogeneic cell therapy platform to address both tau-mediated pathology and associated inflammation in neurodegenerative diseases like Alzheimer's. The awardee, the Regents of the University of Minnesota, will evaluate chimeric antigen receptor (CAR) designs to target pathogenic tau protein and leverage gene editing to deactivate inflammatory genes in the...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $374,000.00 to the University of California, Los Angeles (UCLA) to develop and evaluate a novel hematopoietic stem cell-based chimeric antigen receptor (CAR) macrophage therapy for Alzheimer's disease.
The research project aims to leverage CAR technology, which has demonstrated success in cancer treatment, to target amyloid-beta aggregates and reduce central nervous system...
This $842,114 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to systematically investigate the molecular mechanisms of brain senescence in different molecular subtypes of Alzheimer's disease (AD). The multidisciplinary research team will utilize a "senome" multi-omics approach to provide a comprehensive molecular portrait of senescent cells in the hippocampus of AD patients versus healthy controls. This will involve profiling gene...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $430,884 to Vanderbilt University to investigate the use of engineered astrocytes and microglia as programmable agents to deliver targeted neuroprotective therapies for Alzheimer's disease. The project aims to develop a synthetic biology platform that enables these central nervous system cells to produce therapeutic biologics in response to hallmarks of Alzheimer's pathology, such as...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,274,993.00 to Epicypher, Inc. to develop a new genomic technology called "Reverse Transcribe & Tagmentation (RT & TAG)" for the study of chromatin-associated RNAs (CARNAs) and nascent transcripts. The goal is to enable enhanced research capabilities for understanding the role of CARNAs in aging processes, Alzheimer's disease, and related neurodegenerative conditions. The...
This $500,000 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) will support Sxrna Technologies, Inc. in developing an organoid toolkit for Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD). The company aims to create a platform for identifying senescent cells in living tissue, which can provide insights into the aging process and enable high-throughput drug screening in complex 3D tissue models. Specifically, the grant will fund...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $460,625 to the University of Massachusetts Medical School to dissect the role of cellular senescence in the pathogenesis of Alzheimer's disease (AD).
The researchers will use human induced pluripotent stem cell-based AD models to independently activate the p53/p21 and p16 senescence pathways in differentiated cortical neurons and cerebral organoids. This approach aims to uncover the...